Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)Fiona McPhee, Paul M. Scola, Kathy Mosure et al.|Antimicrobial Agents and Chemotherapy|2012Cited by 186
The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionPaul M. Scola, Jialong Zhu, Li‐Qiang Sun et al.|Journal of Medicinal Chemistry|2014Cited by 112
Discovery and Early Clinical Evaluation of BMS-605339, a Potent and Orally Efficacious Tripeptidic Acylsulfonamide NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionPaul M. Scola, Fiona McPhee, Alan Xiangdong Wang et al.|Journal of Medicinal Chemistry|2014Cited by 69
Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease InhibitorKathleen Mosure, Michael Sinz, Jay O. Knipe et al.|Journal of Pharmaceutical Sciences|2015Cited by 32
CCDC 984481: Experimental Crystal Structure DeterminationPaul M. Scola, Fiona McPhee, Alan Xiangdong Wang et al.|The Cambridge Structural Database|2014Cited by 0